Your browser doesn't support javascript.
loading
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.
Vermersch, Patrick; Galazka, Andrew; Dangond, Fernando; Damian, Doris; Wong, Schiffon L; Jack, Dominic; Harty, Gerard.
Affiliation
  • Vermersch P; Inserm U1172, CHU Lille, FHU Imminent, University of Lille, Lille, France.
  • Galazka A; Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.
  • Dangond F; EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany.
  • Damian D; EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany.
  • Wong SL; EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany.
  • Jack D; Merck KGaA, Darmstadt, Germany.
  • Harty G; Merck KGaA, Darmstadt, Germany.
Curr Med Res Opin ; 37(3): 459-464, 2021 03.
Article in En | MEDLINE | ID: mdl-33331183
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Clinical_trials Limits: Humans Language: En Journal: Curr Med Res Opin Year: 2021 Type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Clinical_trials Limits: Humans Language: En Journal: Curr Med Res Opin Year: 2021 Type: Article Affiliation country: France